> top > docs > PMC:7205724 > spans > 10726-11458 > annotations

PMC:7205724 / 10726-11458 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
353 392-395 Gene denotes CRP Gene:1401
354 234-242 Species denotes patients Tax:9606
355 318-326 Species denotes patients Tax:9606
356 457-465 Species denotes patients Tax:9606
357 475-484 Species denotes SARS-CoV2 Tax:2697049
358 547-556 Species denotes SARS-CoV2 Tax:2697049
359 255-263 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T75 83-89 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T76 103-111 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T77 357-367 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T78 435-441 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T79 485-488 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T80 533-539 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T81 619-625 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T82 725-731 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T67 255-263 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T68 475-479 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T69 547-551 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T113 0-1 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T114 15-17 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T115 28-31 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T116 83-89 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T117 230-233 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T118 314-317 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T119 378-379 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T120 435-441 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T121 533-539 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T122 619-625 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T123 725-731 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T121 159-176 Chemical denotes anti-viral agents http://purl.obolibrary.org/obo/CHEBI_22587

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T6 32-44 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigated http://purl.bioontology.org/ontology/MEDDRA/10062026
T7 357-373 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes lymphocyte count http://purl.bioontology.org/ontology/MEDDRA/10025251

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T82 485-488 Chemical denotes RNA http://purl.obolibrary.org/obo/CHEBI_33697

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T82 255-263 Species denotes COVID-19 NCBItxid:2697049
T83 475-484 Species denotes SARS-CoV2 NCBItxid:2697049
T84 547-556 Species denotes SARS-CoV2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T92 0-264 Sentence denotes A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19.
T93 265-396 Sentence denotes The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP.
T94 397-566 Sentence denotes Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative.
T95 567-732 Sentence denotes There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma.

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
354 234-242 Species denotes patients Tax:9606
359 255-263 Disease denotes COVID-19 MESH:C000657245
355 318-326 Species denotes patients Tax:9606
353 392-395 Gene denotes CRP Gene:1401
356 457-465 Species denotes patients Tax:9606
357 475-484 Species denotes SARS-CoV2 Tax:2697049
358 547-556 Species denotes SARS-CoV2 Tax:2697049

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1222 392-395 Protein denotes CRP https://www.uniprot.org/uniprot/Q5U0J2|https://www.uniprot.org/uniprot/Q07203|https://www.uniprot.org/uniprot/Q01687|https://www.uniprot.org/uniprot/P97315|https://www.uniprot.org/uniprot/P67967|https://www.uniprot.org/uniprot/P67966|https://www.uniprot.org/uniprot/P47875|https://www.uniprot.org/uniprot/P32965|https://www.uniprot.org/uniprot/P21291|https://www.uniprot.org/uniprot/P08462|https://www.uniprot.org/uniprot/A8K268

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T94687 0-1 DT denotes A
T22655 2-7 NN denotes pilot
T19573 8-13 NN denotes study
T23972 14-15 -LRB- denotes [
T55337 15-17 CD denotes 11
T96728 17-18 -RRB- denotes ]
T92410 19-27 RB denotes recently
T26265 28-31 VBZ denotes has
T35997 32-44 VBN denotes investigated
T92380 45-48 DT denotes the
T38590 49-55 NN denotes safety
T37156 56-59 CC denotes and
T24661 60-66 NN denotes effect
T94632 67-69 IN denotes of
T56352 70-82 JJ denotes convalescent
T65134 83-89 NN denotes plasma
T64844 90-94 WDT denotes that
T95987 95-102 VBP denotes contain
T86655 103-111 NN denotes antibody
T45118 112-118 NNS denotes levels
T26321 119-125 JJR denotes higher
T17226 126-130 IN denotes than
T2522 131-132 CD denotes 1
T48589 132-133 -COLON- denotes :
T90182 133-136 CD denotes 640
T89317 137-145 VBN denotes combined
T28925 146-150 IN denotes with
T68950 151-158 JJ denotes regular
T58621 159-169 JJ denotes anti-viral
T22929 170-176 NNS denotes agents
T50644 177-180 CC denotes and
T63224 181-189 JJ denotes standard
T22041 190-200 JJ denotes supportive
T89053 201-205 NN denotes care
T94835 206-208 IN denotes on
T20257 209-217 JJ denotes clinical
T49329 218-226 NNS denotes outcomes
T91601 227-229 IN denotes of
T6238 230-233 CD denotes ten
T3048 234-242 NNS denotes patients
T18696 243-247 IN denotes with
T93206 248-254 JJ denotes severe
T71443 255-263 NN denotes COVID-19
T46997 265-268 DT denotes The
T7672 269-274 NN denotes study
T83098 275-281 VBD denotes showed
T5017 282-290 JJ denotes clinical
T96870 291-302 NN denotes improvement
T42442 303-305 IN denotes of
T61149 306-309 PDT denotes all
T89276 310-313 DT denotes the
T53728 314-317 CD denotes ten
T50396 318-326 NNS denotes patients
T59179 327-338 VBN denotes accompanied
T83510 339-341 IN denotes by
T2183 342-344 DT denotes an
T4240 345-353 NN denotes increase
T18383 354-356 IN denotes in
T99269 357-367 NN denotes lymphocyte
T12131 368-373 NN denotes count
T36613 374-377 CC denotes and
T91622 378-379 DT denotes a
T39579 380-388 NN denotes decrease
T72559 389-391 IN denotes in
T31686 392-395 NN denotes CRP
T20580 397-406 VBG denotes Following
T23341 407-418 NN denotes transfusion
T23846 419-421 IN denotes of
T23496 422-434 JJ denotes convalescent
T68740 435-441 NN denotes plasma
T74721 441-442 -COMMA- denotes ,
T3255 443-446 PDT denotes all
T47829 447-450 DT denotes the
T16466 451-456 CD denotes seven
T26913 457-465 NNS denotes patients
T47643 466-469 WP denotes who
T10299 470-474 VBD denotes were
T19318 475-484 NN denotes SARS-CoV2
T2642 485-488 NN denotes RNA
T76428 489-497 JJ denotes positive
T59448 498-504 IN denotes before
T49967 505-516 NN denotes transfusion
T2352 517-519 IN denotes of
T3020 520-532 JJ denotes convalescent
T57517 533-539 NN denotes plasma
T55829 540-546 VBD denotes turned
T39392 547-556 NN denotes SARS-CoV2
T26456 557-565 JJ denotes negative
T52249 567-572 EX denotes There
T13795 573-577 VBD denotes were
T15563 578-580 DT denotes no
T53693 581-588 NN denotes control
T35357 589-595 NNS denotes groups
T16756 596-605 VBG denotes receiving
T53621 606-618 JJ denotes convalescent
T81904 619-625 NN denotes plasma
T11852 626-631 RB denotes alone
T58859 632-634 CC denotes or
T35171 635-643 JJ denotes standard
T39367 644-651 NN denotes therapy
T20306 652-659 IN denotes without
T63670 660-672 JJ denotes convalescent
T44856 673-680 NN denotes therapy
T15733 681-683 TO denotes to
T71428 684-692 VB denotes evaluate
T29390 693-696 DT denotes the
T54708 697-701 JJ denotes main
T64138 702-708 NN denotes effect
T21425 709-711 IN denotes of
T75685 712-724 JJ denotes convalescent
T78861 725-731 NN denotes plasma
R32394 T22929 T58621 arg1Of agents,anti-viral
R12539 T22929 T50644 arg1Of agents,and
R32883 T89053 T50644 arg2Of care,and
R99734 T89053 T63224 arg1Of care,standard
R84751 T89053 T22041 arg1Of care,supportive
R58957 T48589 T94835 arg1Of :,on
R75573 T49329 T94835 arg2Of outcomes,on
R52082 T19573 T94687 arg1Of study,A
R65194 T19573 T22655 arg1Of study,pilot
R95106 T19573 T23972 arg1Of study,[
R42168 T55337 T23972 arg2Of 11,[
R95339 T96728 T23972 arg3Of ],[
R78448 T35997 T92410 arg1Of investigated,recently
R65706 T19573 T26265 arg1Of study,has
R73941 T35997 T26265 arg2Of investigated,has
R20951 T19573 T35997 arg1Of study,investigated
R83087 T37156 T35997 arg2Of and,investigated
R97536 T37156 T92380 arg1Of and,the
R32731 T38590 T37156 arg1Of safety,and
R69272 T24661 T37156 arg2Of effect,and
R40627 T37156 T94632 arg1Of and,of
R73729 T65134 T94632 arg2Of plasma,of
R7895 T65134 T56352 arg1Of plasma,convalescent
R7377 T37156 T64844 arg1Of and,that
R67249 T37156 T95987 arg1Of and,contain
R70225 T45118 T95987 arg2Of levels,contain
R10830 T45118 T86655 arg1Of levels,antibody
R61261 T45118 T26321 arg1Of levels,higher
R50969 T26321 T17226 arg1Of higher,than
R4008 T48589 T17226 arg2Of :,than
R30054 T2522 T48589 arg1Of 1,:
R45762 T90182 T48589 arg2Of 640,:
R9970 T48589 T89317 arg2Of :,combined
R87348 T89317 T28925 arg1Of combined,with
R60332 T50644 T28925 arg2Of and,with
R69387 T22929 T68950 arg1Of agents,regular
R98484 T49329 T20257 arg1Of outcomes,clinical
R34116 T49329 T91601 arg1Of outcomes,of
R5522 T3048 T91601 arg2Of patients,of
R74118 T3048 T6238 arg1Of patients,ten
R51409 T3048 T18696 arg1Of patients,with
R40479 T71443 T18696 arg2Of COVID-19,with
R90019 T71443 T93206 arg1Of COVID-19,severe
R55615 T7672 T46997 arg1Of study,The
R40867 T7672 T83098 arg1Of study,showed
R64658 T96870 T83098 arg2Of improvement,showed
R66056 T96870 T5017 arg1Of improvement,clinical
R52864 T96870 T42442 arg1Of improvement,of
R70060 T50396 T42442 arg2Of patients,of
R51479 T50396 T61149 arg1Of patients,all
R50628 T50396 T89276 arg1Of patients,the
R30895 T50396 T53728 arg1Of patients,ten
R56320 T36613 T59179 arg1Of and,accompanied
R2541 T50396 T59179 arg2Of patients,accompanied
R80186 T36613 T83510 arg2Of and,by
R38806 T4240 T2183 arg1Of increase,an
R9880 T4240 T18383 arg1Of increase,in
R77420 T12131 T18383 arg2Of count,in
R60391 T12131 T99269 arg1Of count,lymphocyte
R95922 T4240 T36613 arg1Of increase,and
R85485 T39579 T36613 arg2Of decrease,and
R67798 T39579 T91622 arg1Of decrease,a
R82541 T39579 T72559 arg1Of decrease,in
R48725 T31686 T72559 arg2Of CRP,in
R83808 T55829 T20580 arg1Of turned,Following
R25087 T23341 T20580 arg2Of transfusion,Following
R66336 T23341 T23846 arg1Of transfusion,of
R9016 T68740 T23846 arg2Of plasma,of
R27767 T68740 T23496 arg1Of plasma,convalescent
R79010 T55829 T74721 arg1Of turned,","
R49789 T26913 T3255 arg1Of patients,all
R98083 T26913 T47829 arg1Of patients,the
R36266 T26913 T16466 arg1Of patients,seven
R42101 T26913 T47643 arg1Of patients,who
R24725 T26913 T10299 arg1Of patients,were
R12375 T2642 T10299 arg2Of RNA,were
R19448 T2642 T19318 arg1Of RNA,SARS-CoV2
R23710 T2642 T76428 arg1Of RNA,positive
R34529 T10299 T59448 arg1Of were,before
R60141 T49967 T59448 arg2Of transfusion,before
R2931 T49967 T2352 arg1Of transfusion,of
R3822 T57517 T2352 arg2Of plasma,of
R20207 T57517 T3020 arg1Of plasma,convalescent
R30096 T26913 T55829 arg1Of patients,turned
R66579 T26456 T55829 arg2Of negative,turned
R14919 T26456 T39392 arg1Of negative,SARS-CoV2
R49718 T26913 T26456 arg1Of patients,negative
R70070 T52249 T13795 arg1Of There,were
R68506 T35357 T13795 arg2Of groups,were
R94657 T35357 T15563 arg1Of groups,no
R49835 T35357 T53693 arg1Of groups,control
R88768 T35357 T16756 arg1Of groups,receiving
R7103 T58859 T16756 arg2Of or,receiving
R65241 T81904 T53621 arg1Of plasma,convalescent
R80896 T81904 T11852 arg1Of plasma,alone
R48507 T81904 T58859 arg1Of plasma,or
R74990 T39367 T58859 arg2Of therapy,or
R57531 T39367 T35171 arg1Of therapy,standard
R26123 T16756 T20306 arg1Of receiving,without
R11811 T44856 T20306 arg2Of therapy,without
R59105 T44856 T63670 arg1Of therapy,convalescent
R40530 T71428 T15733 arg1Of evaluate,to
R29016 T16756 T15733 modOf receiving,to
R33735 T64138 T71428 arg2Of effect,evaluate
R2474 T64138 T29390 arg1Of effect,the
R56840 T64138 T54708 arg1Of effect,main
R22469 T64138 T21425 arg1Of effect,of
R7749 T78861 T21425 arg2Of plasma,of
R22133 T78861 T75685 arg1Of plasma,convalescent

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T75 83-89 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T76 103-111 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T77 357-367 Body_part denotes lymphocyte http://purl.org/sig/ont/fma/fma62863
T78 435-441 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T79 485-488 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T80 533-539 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T81 619-625 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T82 725-731 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T64 255-263 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T65 475-484 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096
T66 547-556 Disease denotes SARS-CoV2 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T92 0-264 Sentence denotes A pilot study [11] recently has investigated the safety and effect of convalescent plasma that contain antibody levels higher than 1:640 combined with regular anti-viral agents and standard supportive care on clinical outcomes of ten patients with severe COVID-19.
T93 265-396 Sentence denotes The study showed clinical improvement of all the ten patients accompanied by an increase in lymphocyte count and a decrease in CRP.
T94 397-566 Sentence denotes Following transfusion of convalescent plasma, all the seven patients who were SARS-CoV2 RNA positive before transfusion of convalescent plasma turned SARS-CoV2 negative.
T95 567-732 Sentence denotes There were no control groups receiving convalescent plasma alone or standard therapy without convalescent therapy to evaluate the main effect of convalescent plasma.